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Abstract: To gain more insight into the role of cyto­
kines in Pneumocystis carinii pneumonia (PCP) we 
followed pro-inflammatory cytokine profiles in rats with 
steroid-induced PCP at 2-week intervals. The cyto­
kines measured were immunoreactive interleukin-1 (3 
(ILriP), bioactive interleukin-6 (ILr6), and tumor ne­
crosis factor a (TNF-a). In vivo cytokine concentra­
tions were determined in three compartments, i.e., 
bronchoalveolar lavage (BAL) fluid, lung homogenates, 
and plasma. Upopolysaccharide (LPS) -stimulated cyto­
kine production by alveolar cells and in whole-blood 
cultures was measured ex vivo, P  carinii load and host 
inflammatory response, as determined by lung/body 
weight ratio and 111indium-IgG bio distribution were 
monitored throughout developing PCP. IL-1|3 was el­
evated in lung homogenates (6 0 0 , range < 2 0 —1260
pg/mL) and IL-6 in BAL fluid (48, range < 2 0 —115
pg/mL), whereas the pro-inflammatory cytokine con­
centrations were not increased in plasma. Thus in rats 
with PCP elevated pro-inflammatory cytokine concen­
trations were found to be restricted to the lung com­
partments. Corticosteroids did not significantly influ­
ence cytokine concentrations, but showed profound 
inhibitory effects on ex vivo cytokine production. The 
LPS-stimulated cytokine production by alveolar cells 
gradually decreased during the 6  weeks after the start 
o f the steroid injections, whereas the production in 
whole blood cultures was immediately and completely
suppressed. J. Leukoc. BioL 60: 710—715; 1996.
K ey  Wbrds: corticosteroids • interleukin-1 * interleukin-6 * tumor 
necrosis factor a • ulIn-IgG biodistribution * bronchoalveolar la­
vage ■ lung homogenates
studies show that P. carinii possesses binding sites for 
tumor necrosis factor a (TNF-a) and that this cytokine is 
capable of killing P. carinii [3-5]. In mice TNF-a and 
interleukin-1 p (IL-1P) are critical in the clearance of P. ca­
rinii and interleukin-6 (IL-6) was found to regulate pulmo­
nary inflammation and antibody response during resolu­
tion of PCP [6-8]. P, carinii has been reported to stimulate 
in vivo and in vitro production of TNF-a by alveolar macro­
phages [9—14].
Corticosteroids down-regulate pro-inflammatory cyto­
kine production and increase the risk for PCP in patients 
and in animal models [15-18]. We previously described 
cytokine patterns in immunosuppressed HIV seronegative 
and HIV seropositive patients with PCP [19, 20]. In these 
studies corticosteroids did not seem to influence plasma 
cytokine concentrations but we observed strong down- 
regulation of cytokine production in whole blood cultures 
of patients with severe PCP who had been given cortico­
steroids. However, since severe infection in itself can also 
down-regulate pro-inflammatory cytokine production, it 
was impossible to assess the relative contribution of corti­
costeroids and P. carinii pneumonia to the measured cyto­
kine profiles [21, 22].
This prompted us to perform cytokine studies in immu­
nosuppressed rats infected with P. carinii under carefully 
controlled experimental conditions.
MATERIALS AND METHODS
Animal model
Four- to six-week-old female Spraque-Dawley rats with body weights be­
tween 150 and 175 g were immunosuppressed by weekly subcutane-
INTRODUCTION
Pneumocystis carinii pneumonia (PCP) is a common patho­
gen in immunocompromised hosts. Cellular immunity, in 
particular CD4+ lymphocyte-dependent mechanisms, are 
considered important host defense mechanisms against 
Pneumocystis carinii [1, 2]- Evidence to date indicates that 
cytokines, the intercellular messengers involved in many 
inflammatory processes, also play a role in PCP In vitro
Abbreviations: PCP, Pneumocystis carinii pneumonia; IL-l.ß, 
interleukin-lß; IL-6, interleukin-6; TNF-a, tumor necrosis factor a; 
BAL, bronchoalveolar lavage; LPS, lipopolysaccharide; PBS, phosphate- 
buffered saline; ELISA, enzyme-linked immunosorbent assay; AN0VA, 
analysis of variance.
Correspondence: Roos M* Perenboom, Department of General Inter­
nal Medicine, University Hospital Nijmegen, P0B  9101, 6500HB, Nij­
megen, The Netherlands.
Received November 13, 1995; revised September 3, 1996; ac­
cepted September 5, 1996.
7 1 0  Journal o f Leukocyte B iology Volume 60, December 1996
ous injections of 25 mg hydrocortisone and an 8% protein-restricted 
diet. Amoxicillin (1 mg/mL) was added to the drinking water to prevent 
bacterial infections. PCP was induced by close cohabitation with P. 
carimi-infected rats (PCP rats), thereby exposing them passively to 
Ft cariniU which is transmitted by air. Similar to other investigators, we 
lost 15-25%  of the rats before endpoints were reached [23]. Of the 
rats who survived 4  weeks of cohabitation with infected littermates, 
more than 95%  developed PCP. As we have shown before, the second­
ary rats develop a consistent and comparable PCP and the level of in­
fection is standardized by the P. carinii density score (see below). 
Barrier-sustained rats (housed at another level of the animal quarters 
in cages covered with air filters) were subjected to the same immuno­
suppressive regime without development of PCP (steroid rats). Control 
rats were not immunosuppressed, were barrier-sustained, and were 
free of PCP (healthy rats). Viral co-infection was excluded by regular 
serological screening for common rodent viruses. Bacterial or fungal co- 
infection was excluded by microscopic examination of Giemsa-stained 
sm ears of the cut surface of the lung. Body weight was measured weekly.
At 2-week intervals after the start of the immunosuppression, 
J11indium-IgG (^ In -Ig G ) was given intravenously to a group of PCP, 
steroid , and healthy rats as described elsewhere [23]. Two days later 
th e  animals were killed by bleeding and a bronchoalveolar lavage 
(BAL) was performed [24]. Total lung weight before the BAL and 
weights of the separate lung lobes after BAL were measured. The up­
take of ^ I n - I g G  was measured in the right upper lung iobe and in a 
norm al calf muscle sample for reference. P. carinii density was as­
sessed  in Giemsa and silver-stained impression smears and expressed 
in the logarithmic P. carinii density score as described by Bartlett [16]. 
Two individuals who were blinded to the condition of the animals ex­
am ined  the slides and rated them according to the following score: in
one 1 0 0 0  X field >  100 cysts = 5, 1 1 -1 0 0  = 4, 1 -10  = 3, 2 -9  
in 10 1 0 0 0  X fields = 2, 1 in 10 fields = 1, and 0 in 50 fields ~ 0.
Processing BAL fluid and lung tissue
Im m ediately  after BAL the fluid was centrifuged at 500 g fo r 15 min. 
S u p e rn a tan t was removed, aliquoted, and frozen at — 80°C. The pellet 
w as resuspended in Dulbecco’s modified Eagle’s medium at a concen­
tration  of 0 .5  X 106 viable macrophages/mL; viability was assessed by 
trypan  b lue dye exclusion. This was subsequently incubated in 2-mL 
closed  polystyrene tubes (Greiner, Alphen, The Netherlands) in the 
p re sen ce  or absence of lipopolysaccharide (LPS; Escherichia coli sero­
ty p e  0 5 5 :B5, Sigma) at a final concentration of 10 (ig/mL. All incuba­
tions w ere done at 3 7 °C for 24 h in a CO2 incubator. Following incu­
bation  the  tubes were centrifuged at 1200 g  for 10 min and the 
su p e rn a ta n t and cell pellets separately frozen at -8 0 ° C  until cytokine 
analysis. The left upper lung lobe was homogenized in a blender and 
so n ica ted  in a 10-mL phosphate-buffered saline (PBS) solution of pro­
tea se  inhibitors containing 2 mmol phenylmethylsulfonyl fluoride, 1 
m g/L  antipain , 1 mg/L aprotinin, 1 mg/L leupeptin, and 1 mg/L pep- 
statin . T h e  sonicated homogenate was centrifuged at 1200 gfor 15 min 
a n d  the supernatant frozen until cytokine analysis.
Processing whole blood
Blood w as collected aseptically into three 2-mL polystyrene tubes con­
tain ing 2 0  p,L heparin (heparin sodium 5000 IU/mL, LEO Pharma- 
ceuLicals BV, W eesp, The Netherlands). One tube was immediately 
cen trifuged  at 1250  g fo r 10 min; the plasma was transferred to a poly­
p ropy lene  tube and frozen at - 8 0 ° C  until cytokine analysis. To one 
o f  the two remaining tubes LPS was added (final concentration 10 
jlg /m L) to stimulate cytokine production. This tube and the third tube 
w ere incubated at 3 7 °C for 24 h. After incubation the tubes were cen­
trifuged and the supernatant frozen at -8 0 ° C .
Cytokine assays
Plasm a and  BAL samples were analyzed by means of bioassays for IL-6 
a n d  T N F-a, respectively, and enzyme-linked immunosorbent assay 
(ELISA) for IL -ip . IL-6 was measured by use of the B9 hybridoma bio­
assay; TN F-a was measured by the L929 cytotoxicity assay [25, 26]. 
For IL-1 we used a specific rat ELISA (provided by Dr. S. Poole, Na­
tional Institute of Biological Standards, Hertfordshire, UK). The detec­
tion limit of all three assays was 20 pg/mL,
Radiopharmaceutical protocol
u l In-lgG scans and biodistribution are sensitive and quantitative meth­
ods to assess the severity of PCP [23, 27, 28]. n i In-IgG enters inflam­
matory sites via increased vascular permeability, after which the indium 
is split off from the IgG and remains at that site. W e have shown in an 
earlier report that 111 In accumulation in the lung correlates well with 
P, carinii density scores and parameters of host inflammatory re­
sponses [23]. IgG diethylene triamine penta-acetic bicyclic anhydride 
was conjugated to human, nonspecific, polyclonal IgG (Sandoglobulin, 
Sandoz AG, Neurenberg, FRG) according to the method described by 
Hnatowich and colleagues [29]. The conjugated solution was radio- 
labeled with l u In (indium chloride, Mallinckrodt Medical, Petten, 
The Netherlands) via citrate transchelation. Radiochemical purity was 
determined by ITLC-SG chromatography (Gelman Laboratories, Ann 
Arbor, MI) with 0.1 M citrate (pH 5) as the solvent. Labeling efficiency 
was always >  95% .
For biodistribution studies, lung and muscle activity were measured 
48 h after injection of 10 p,g IgG labeled with 1 MBq ^ I n  by count­
ing the tissue samples in a shielded well-type gamma counter. To cor­
rect for radioactive decay and permit calculation of the uptake of the 
radiopharmaceuticals in each organ as a fraction of the injected dose, 
aliquots of the respective dose were counted simultaneously. The activ­
ity measured in tissues was expressed as percentage of injected dose 
per gram. Lung-to-muscle ratios were calculated.
Statistics
Data on P. carinii density score, lung-to-body weight ratio, and 111 In- 
IgG uptake, were normally distributed and are therefore given in means 
and standard error ( s e )  and analyzed by Students’s i-test. Cytokine con­
centrations and production did not follow Gaussian distributions and 
are therefore given in medians and ranges and analyzed with the non- 
parametric Mann-Whitney test. Lung-to-body weight ratios, 1]1In-IgG 
uptake, and the various cytokine concentrations and production capac­
ities were evaluated as parameters for inflammation using a one-way 
analysis of variance (ANOVA), including a Bonferonni correction to 
compensate for multigroup testing. Linear regression coefficients were 
calculated.
The study was approved by ihe University Committee on Animal 
Experiments.
RESULTS
4
Development of PCP and host inflammatory 
responses’
P. carinii density in lungs of rats exposed to P. carinii- 
infected littermates steadily increased during the 6 weeks 
after the start of immunosuppression (Fig. 1A). Similarly, 
host inflammatory reaction, expressed in terms of lung- 
to-body weight (L/B) ratio (Fig. IB) and u l In-IgG lung-to - 
muscle biodistribution (L/M ratio, Fig. 1C) increased every
2 weeks. Both ratios were correlated with the P. carinii 
density score (r = 0.8, P  <  0.0001).
Although the L/B ratio of steroid rats also slightly in­
creased over time, the ratio was always higher in PCP rats. 
L/M ratios in PCP rats were significantly higher than in ste­
roid rats or healthy rats at weeks 4 and 6.
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Fig. 1. Parameters of inflammation in steroid induced Pneumocystis 
carinii pneumonia in rats; P. carinii density in the lung (A), relative lung 
weight (B), and relative uptake of l l l In-IgG in the lung (C). Steroid rats 
(hatched bars) are rats immunosuppressed with weekly injections of 
hydrocortisone and a protein-restricted diet, free of PCP, PCP rats 
(filled bars) are rats subjected to the same immunosuppressed regimen 
with severe PCP at week 6. Healthy control rats (open bars) were not 
immunosuppressed and free of PCP. Number of rats killed: control 
rats, 8; PCP rats, 7 at week 2, 6 at week 4, 5 at week 6; steroid rats,
4 at each time point. * Statistical significance ( P <  0 .05 , Student’s ¿-test).
Cytokine concentrations in BAL and lung 
homogenates
Immunoreactive IL-1(3 was present in BAL fluid of healthy 
rats at a concentration of 280 pg/mL (range <20-640 
pg/mL; Fig. 2A). The median IL-13 concentrations in 
BAL in steroid and PCP rats were lower, these differences 
were, however, not significant.
In lung homogenates of PCP rats IL-iP concentrations 
at weeks 4 and 6 were significantly higher than in steroid 
or healthy rats (week 6: 600, range <20-1260 vs. 43, 
range 27-320, respectively, <20, range <20-380 pg/mL,
P <  0.05; Fig. 2B).
Bio active IL-6 could not be detected in BAL fluid of 
healthy rats or immunosuppressed rats. However, IL-6 was 
found in BAL fluid of rats with PCP at week 4 and 6, with 
the highest concentration at week 4 (Fig. 2C). Although 
these IL-6 concentrations were relatively low (48, range 
<20-115 pg/mL), the differences with healthy and steroid 
rats were significant (P < 0.05). IL-6 could not be found 
in lung homogenates of rats in any of these groups. Bio­
active TNF-a could not be detected in BAL fluid or lung 
homogenates of rats in any group.
Cytokine concentrations in plasma
4
IL-6 was present in plasma (21-136 pg/mL) from 6 of the 
19 immunosuppressed rats in week 4 and 6 irrespective 
of the presence of PCP. Although IL-6 could not be de­
tected in the plasma of healthy rats, the differences be­
tween PCP and healthy rats were not significant. Bioactive 
TNF-a and immunoreactive IL-1(3 could not be detected
in the plasma of the rats in any group.
Ex vivo cytokine production by alveolar cells
LPS-stimulated production of IL-1 [3, IL-6, and TNF-a 
gradually decreased over the 6-week period in both steroid 
and PCP rats, with a slower decline in PCP rats (Fig. 3).
At week 4 the production of pro-inflammatory cytokines 
was higher in PCP than in steroid rats, although this differ­
ence was only significant for IL-6. In the absence of LPS, 
ex vivo cytokine production of alveolar cells was generally 
low (<400 pg/mL); however, in week 4 significant amounts
of IL-6 (747, range 20-2650 pg/mL) and TNF-a (545,
range <20-2400 pg/mL) secretion was. found in the non­
stimulated culture supernatant in PCP rats.
Ex vivo production in whole-blood cultures
In healthy rats, LPS-stimulated production of IL-1 (3 was 
500, range 200-786 pg/mL and of IL-6 2250, range 
600-5000 pg/mL. Both in PCP and steroid rats IL-1 P
and IL-6 production was almost completely suppressed 
from week 2 onward (Fig. 3, D and E).
In the absence of LPS ex vivo production of pro- 
inflammatory cytokines was around the detection limit, 
with an exception for IL-6 in steroid rats at weeks 4 and
7 1 2  Journal o f Leukocyte B iology Volume 60, December 1996
A
1000
- I
I
0>a
*
ca
3
100 r
10
Correlations between cytokine patterns and 
parameters of inflammation
Cytokine concentrations in BAL, lung homogenates, of 
plasma did not correlate with the other inflammatory pa­
rameters. The LPS-stimulated production of TNF-a and 
IL-6 by alveolar cells in steroid rats was inversely corre­
lated with L/B ratios (.r = —0.63, P  = 0.01, respectively, 
r =  -0 .7 2 , P  = 0.002). There was no correlation with 
L/M ratios. The LPS-stimulated production of IL-6 by al­
veolar cells in PCP rats was inversely correlated with L/B 
ratios (r = —0.58, P  = 0.02) as well as with L/M ratios 
(r = —0.61, P  = 0.01). Production in whole-blood cul­
tures did not correlate with other inflammatory parameters.
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In this study on experimental PCP in rats, pro-inflamma­
tory cytokine concentrations were followed in BAL fluid, 
lung homogenates, and plasma and were compared with 
those in rats subjected to the same immunosuppressive 
regime but without PCP (steroid rats) and with those of 
healthy rats. In rats with PCP, elevated pro-inflammatory 
cytokine concentrations were found in the lung compart­
ments at weeks 4 and 6* i.e., IL-1(3 in lung homogerxates 
and IL-6 in BAL fluid. Why different pro-inflammatory 
cytokines are present in the different lung compartments 
requires further study. The explanation is most likely multi- 
factorial and may reflect relative differences in cytokine- 
producing cell populations, presence of other inflamma­
tory proteins, and presence or absence of surfactant in the 
different lung compartments. The presence of pro-inflam­
matory cytokine concentrations in the lung is supported by 
the results obtained with ex vivo production of cytokines. 
At week 4, when the infection is clearly established and 
all PCP rats have elevated P. carinii density scores, alve­
olar cells of PCP rats spontaneously produced substantial 
amounts of IL-1(3 and IL-6 and their LPS-stimulated pro­
duction was higher than in steroid rats. This could point 
to activation of these cells in vivo. Previously we observed 
a similar pattern in patients with PCP, showing increased 
pro-inflammatory cytokine concentrations in BAL fluid 
[19,20]. In HIV-seronegative/PCP-positive patients on long­
term corticosteroids, immunoreactive TNF-a was found to 
be increased in BAL fluid, whereas in HIV-seropositive pa­
tients IL-1JJ was found to be increased. In this study on 
rat PCP, we used a TNF-a bioassay and the undetectable 
concentrations of TNF-a in BAL and lung homogenates 
may be due to the presence of inhibitors, such as soluble 
TNF-a receptors. A reliable immunoassay for rat-TNF-a 
was not available to us.
Our finding of undetectable bioactive TNF-a levels in 
whole-blood cultures, even following LPS stimulation,
6 (150, range <20-365 pg/mL, respectively, 340, range differs from the findings of Wright et al. [30]. Differences
Fig. 2 .  Concentrations of immunoreactive IL-ip in BAL fluid (A) and 
lung homogenates (B) and of bioactive IL-6 in BAL (C) in PCP rats 
(filled triangles), steroid rats (filled circles), and control rats (open cir­
cles). D ata  are given in median (symbol) and range (vertical lines). Ste­
roid rats are rats immunosuppressed by weekly injections of hydrocor­
tisone and a pro Lein-restricted diet, free of PCP. PCP rats are rats 
subjected to the same immunosuppressed regimen with severe PCP at 
week 6. Number of rats killed: control rats, 8; PCP rats, 7 at week 2, 
6  at w e e k  4 , 5 at week 6; steroid rats 4 at each time point. * Statistical 
significance (P <  0 .05 , Mann-Whitney test).
< 2 0 —570 pg/mL).
Bio active TNF-a could not be detected in whole-blood 
cultures.
in animal model (rabbit vs. rat) and bioassay (WEHI vs, 
L929 bioassay) may explain the discrepancy.
Similar to our data in humans with PCP, plasma con-
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Fig. 3. Time course of LPS-stimulated production of IL-1 (3 (A), IL-6 
(B), and TNF-a (C) by alveolar cells and of IL-1 P (D) and IL-6 (E) in 
whole blood cultures in PCP rats (filled triangles), steroid rats (filled cir­
cles), and healthy rats (open circles). Data are given in median (symbol) 
and range (vertical lines). Steroid rats are rats immunosuppressed by 
■weekly injections of hydrocortisone and a protein-restricted diet, free 
of PCP. PCP rats are rats subjected to the same immunosuppressed reg­
imen with severe PCP at week 6. Number of rats killed: healthy rats, 
8; PCP rats, 7 at week 2, 6 at week 4-, 5 at week 6; steroid rats 4 at 
each time point. * Statistical significance (P  <  0.05, Mann-Whitney test).
centrations of pro-inflammatory cytokines were not ele­
vated in PCP rats, pointing to a compartmentalization of 
the pro-inflammatory cytokines in the lungs. One may spec­
ulate that the pro-inflammatory cytokines are needed in 
the lung to neutralize P. carinii, whereas the body should 
be protected from the deleterious effects of pro-inflamma­
tory cytokines in the circulation.
Apparently the effect of steroids on systemic and local 
cytokine concentrations are limited, as these concentra­
tions were not significandy different between healthy and 
steroid rats. These findings are consistent with our data in 
patients with PCP, which showed that cytokine concentra­
tions did not differ between steroid-treated and non­
steroid-treated patients [19, 20].
The ex vivo production, however, was profoundly influ­
enced by corticosteroids administered in vivo. LPS- 
stimulated pro-inflammatory cytokine production by alve­
olar cells in both PCP rats and steroid rats was not imme­
diately suppressed, since it took 6 weeks before complete 
suppression was reached. These findings refute the sugges­
tion of Huang et al. that the beneficial effect of steroids 
on the clinical course of PCP is due to immediate suppres­
sion of the pro-inflammatory cytokine production by alve­
olar cells [31].
Although ex vivo cytokine production in whole blood cul­
tures was also influenced by corticosteroids, the time 
course was different; in these cultures the cytokine produc­
tion was immediately and profoundly suppressed. No pro­
duction could be elicited at week 2, whereas a slight re­
covery was seen at weeks 4 and 6. This pattern was similar 
in PCP and steroid rats, suggesting a profound influence 
of steroids on the systemic cytokine response.
The differential effect of steroids on cytokine produc­
tion in alveolar cells and blood is in agreement with the
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findings in patients with PCP. In steroid-treated HIV- 
seropositive patients with PCP, production of immunoreac­
tive IL-6 and TNF-a in whole-blood cultures was sup­
pressed while the production in alveolar cells was not 
affected [20]. It also accords with the in vitro findings of 
Strieter et aL, who showed that the effects of steroids on 
TNF-a production were more pronounced in peripheral 
blood monocytes than in alveolar macrophages [32]. In 
PCP in rats, the relative u l In-IgG uptake in the lung 
(L/M ratio) seems to be a better parameter of inflammation 
than the relative body, weight, as it discriminates better be­
tween steroid-treated rats with and without PCP and 
hardly differs between healthy and uninfected steroid rats.
Although concentrations of IL-6 and IL-1 (3 were ele­
vated in weeks 4 and 6, when there was established PCP, 
they did not correlate with the other inflammatory param­
eters, L/B and 1}1In-IgG L/M ratios. This was similar to 
our findings in patients, showing no correlation between 
cytokine concentrations and clinical severity of the disease
[19, 20].
Despite some differences, the steroid-induced PCP in 
the rat is a good model for human steroid-induced PCP 
and suitable to study the effect of cytokine modulation on
the course of PCP.
ACKNOW LEDGM ENTS
This study was supported by a grant from the Program co­
ordination committee for AIDS research (PccAO) in the 
Netherlands.
We would like to express our gratitude for the expert 
help of Gerry Grutters and Henny Eikholt of the Central 
Animal Laboratory, of Emiel Koenders of the Nuclear 
Medicine Department and of Tita Oettinger of the Depart­
m ent of Parasitology. We thank the European Concerted 
Action group Biomed-I (contract no. BMH1-CT94-1118) 
on Pneumocystosis for their help in obtaining P . c a r in i i -  
infected rats and the fruitful discussions during the regular 
meetings.
REFERENCES
1. Harmsen, A. G., Stanckiewicz, M. (1990) Requirement for CD4+ cells in 
resistance to Pneumocystis carinii pneumonia in mice. J. Exp. Med, 172,
937-945 .
2« Shellito, J., Suzara, V. V., Blumenfeld, W., Beck, J. M., Steger, H. J., Er- 
mak, T. H. (1990) A new model of Pneumocystis carinii infection in mice 
selectively depleted of helper T lymphocytes. J. Clin. Invest. 85, 1686-
1693.
3. Donta, S. T., Pesanti, E. L. (1990) Tumor necrosis factor-a binds to specific 
receptors on Pneumocystis carinii. Clin. Res. 38, 352A (Abstract).
4 . Pesanti, E. L. (1991) Interaction of cytokines and alveolar cells with Pneu­
mocystis carinii in vitro. J. Infect. Dis. 163, 611-616,
5. Pesanti, E. L., Tomicic, T., Donta, S. T. (1991) Binding of 125I-labelled 
tumor necrosis factor to Pneumocystis carinii and an insoluble cell wall frac­
tion. J. ProtozooL 38, 28S-29S (Abstract).
6 . Chen, W., Havell, E. A., Gigliotti, E, Harmsen, A. G. (1993) Interleukin-6 
production in a murine model of Pneumocystis carinii pneumonia: Relation 
to resistance and inflammatory response. Infect. Immun. 61, 97-102.
7. Chen, W., Havell, E. A., Moldawer, L. L., et al. (1992) Interleukin-1: An
important mediator of host resistance against Pneumocystis carinii. J. Exp.
Med. 176, 713-718.
8 . Chen, W., Havell, E. A., Harmsen, A. G. (1992) Importance of endogenous
tumor necrosis factor alpha and gamma interferon in host resistance against 
Pneumocystis carinii infection. Infect Immun. 60 , 1279-1284.
9. Hoffman, 0, A,, Standing, J. E., Limper, A. H. (1993) Pneumocystis carinii 
stimulates tumor necrosis factor-a release from alveolar macrophages 
through a p-glucan-me dialed mechanism. J. Immunol. 150, 3932-3940.
10. Kandil, 0., Fisman, J. A., Koziel, H,, Pinkston, P., Rose, R. M., Remold, 
H, G. (1994) Human immunodeficiency virus type 1 infection of human 
macrophages modulates the cytokine response to Pneumocystis carinii. In­
fect. Immun. 62 , 644-650,
11. Kolls, J, K., Beck, J. M., Nelson, S., Summer, W. R., Shellito, J. (1993) Al­
veolar macrophage release of tumor necrosis factor during murine Pneu­
mocystis carinii pneumocystis. Am. J. Respir. Cell Mai, Biol. 8, 370-376.
12. Krishnan, V. L., Meager, A., Mitchell, D. M., Pinching, A. J. (1990) Al­
veolar macrophages in AIDS patients ¡increased spontaneous tumour necro­
sis factor-alpha production in Pneumocystis carinii pneumonia. Clin. Exp.
Immunol, 80, 156-160,
13. Tamburrini, E., De Luca, A., Ventura, G< et al, (1991) Pneumocystis carinii 
stimulates in vitro production of tumor necrosis factor-a by human macro­
phages. Med. Micribiol. Immunol. 180, 15-20,
14. Theus, S. A., Linke, M. J,, Andrews, R, P., Walzer, R D. (1993) Proliferative 
and cytokine responses to a major surface glycoprotein of Pneumocystis ca­
rinii. Infect. Immun. 61 , 4703-4709.
15. Amano, Y., Lee, S. W., Allison, A. C. (1992) Inhibition by glucocortico- 
steroids of the formation of interleukin-1 a  and interleukin-1 (3 and 
interleukin-6 : mediation by decreased mRNA stability. MoL Pharmacol. 
4 3 , 176-182,
16. Bartlett, M. S., Queener, S. F,, Jay, M. A., Durkin, M. M., Smith, J. W. 
(1987) Improved rat model for studying Pneumocystis carinii pneumonia, 
J. Clin. Microbiol 2 5 , 480-484.
17. Sepkowilz, K. A. (1993) Pneumocystis carinii pneumonia in patients with­
out AIDS. Clin. Infect, Dis, 17 (Supp). 2), S416—S422.
18. Peces, R., Urra, J. M., Gorostidi, M., Lopez-Larrea, C. (1992) Role of 
maintenance immunosuppression and methylprednisone in OKT3-induced 
cytokine release. Transplant. Proc. 24 , 2596-2599.
19. Perenboom, R. M., Van Schijndel, J. C. H. W., Beckers, P. et al. (1996) 
Cytokine profiles in BAL and blood in HIV seronegative patients with Pneu­
mocystis carinii pneumonia. Eur. I. Clin. Invest. 2 6 , 159-166.
20. Perenboom, R, M., Sauerwein, R. W., Beckers, P. et al. (1995) Cytokine 
profiles in broncho-alveolar lavage fluid and blood in HIV negative and 
HIV seropositive patients with PCP, Cytokine 7, 601 (Abstract).
21. Keuter, M., Dharmana, E., Hussein Gasem, M. et al. (1994) Patterns of 
proinflammatory cytokines and inhibitors during typhoid fever. J. Infect.
Dis. 169, 1306-1311.
22. Van Deuren, M,, van der Ven-Jongekrijg, J., Demacker, P. N. M. et al. 
(1994) Differential expression of proinflammatory cytokines and their in­
hibitors during the course of meningococcal infections. J. Infect. Dis. 169,
157-161.
23. Perenboom, R. M.> Oyen, W. J. G,, van Schijndel, J, C. H. W., Beckers, 
P,, Corstens, F. H. M., van der Meer, J. W. M. (1995) Serial 111 In-labelled 
IgG biodistribution in rat Pneumocystis carinii pneumonia: A tool to mon­
itor the course and severity of the infection. Eun J. Nuclear Med. 122 ,
1129-1132.
24. Mauderly, J. L. (1977) Bronchopulmonary lavage of small laboratory ani­
mals. Lab. Animal ScL 27 , 255-261.
25. Aarden, L. A,, de Groot, E, R,, Schaap, D. L,, Lansdorp, P. M. (1987) Pro­
duction of hybridoma growth factor by human monocytes. Eur. J. Immunol.
17, 1411-1416.
26. Aggarwal, B. B. (1985) Human lymphotoxin. Methods Enzytnol. 116, 
441—444.
27. Fishman, J, A,, Strauss, H. W., Fishman* A. J., Neddelman, M., Callahan, 
R., Kwah, B. A., Rubin, R. H. (1993) Imaging of Pneumocystis carinii pneu­
monia with m In-labeled non-specific polyclonal IgG: an experimental 
study in rats. NucL Med. Camniun. 6 5 , 147—157.
28. Claessens, R. A. J, M., Koenders, E. B., Boerman, 0. C., Oyen, W. J. G., 
Borm, G. E, van der Meer, J. W, M., Corstens, F. H. M. (1995) Dissociation 
of indium from indium-111 labeled dielhylene triamine pentaacetic acid 
conjugated non-specific polyclonal human immunoglobulin G in inflamma­
tory foci. Eun f. Nucl. Med. 22 , 212-219.
29. Hnatowich, D. J., Childs, R. L., Lanteigne, D., Najafi, A. (1983) The prep­
aration of DTPA-coupled antibodies radiolabeled with metallic radionu­
clides; an improved method. J. Immunol. Meth. 65 , 147-157.
30. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevilch, R. J., Mathison, J. C, 
(1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and 
LPS binding protein. Science 249 , 1431-1433.
31. Huang, 2. B., Eden, E. (1993) Effect of corticosteroids on IL-1 P and TNF- 
a  release by alveolar macrophages from patients with AIDS and PCP. Chest
104, 751-755.
32. Strieter, R. M., Remick, D, G., Lynch, J. P. et al. (1989) Differential reg­
ulation of tumour necrosis factor-alpha in human alveolar macrophages and 
peripheral blood monocytes: a cellular and molecular analysis. Am. J. Res­
pir. Cell MoL Biol. 1, 57-63,
